EP1231921A4 - Inhibiteurs de proteases - Google Patents
Inhibiteurs de proteasesInfo
- Publication number
- EP1231921A4 EP1231921A4 EP00977065A EP00977065A EP1231921A4 EP 1231921 A4 EP1231921 A4 EP 1231921A4 EP 00977065 A EP00977065 A EP 00977065A EP 00977065 A EP00977065 A EP 00977065A EP 1231921 A4 EP1231921 A4 EP 1231921A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- protease inhibitors
- protease
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16457699P | 1999-11-10 | 1999-11-10 | |
US164576P | 1999-11-10 | ||
PCT/US2000/030703 WO2001034158A1 (fr) | 1999-11-10 | 2000-11-08 | Inhibiteurs de proteases |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1231921A1 EP1231921A1 (fr) | 2002-08-21 |
EP1231921A4 true EP1231921A4 (fr) | 2004-06-23 |
Family
ID=22595118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00977065A Withdrawn EP1231921A4 (fr) | 1999-11-10 | 2000-11-08 | Inhibiteurs de proteases |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1231921A4 (fr) |
JP (1) | JP2003513926A (fr) |
WO (1) | WO2001034158A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
CZ20012277A3 (cs) * | 1998-12-23 | 2001-11-14 | Smithkline Beecham Corporation | Inhibitory proteázy |
EP1232155A4 (fr) | 1999-11-10 | 2002-11-20 | Smithkline Beecham Corp | Inhibiteurs de protease |
WO2001034600A1 (fr) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Inhibiteurs de protease |
JP2003513924A (ja) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
SK13632002A3 (sk) | 2000-03-21 | 2003-02-04 | Smithkline Beecham Corporation | C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty |
CO5280093A1 (es) * | 2000-04-18 | 2003-05-30 | Smithkline Beecham Corp | Metodos de tratamiento |
CA2412353A1 (fr) * | 2000-06-14 | 2001-12-20 | Smithkline Beecham Corporation | Inhibiteurs de proteases |
KR20220115062A (ko) | 2021-02-09 | 2022-08-17 | (주)오스티오뉴로젠 | 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038687A1 (fr) * | 1998-12-23 | 2000-07-06 | Smithkline Beecham Corporation | Inhibiteurs de proteases |
WO2001095911A1 (fr) * | 2000-06-14 | 2001-12-20 | Smithkline Beecham Corporation | Inhibiteurs de proteases |
WO2002017924A1 (fr) * | 2000-09-01 | 2002-03-07 | Smithkline Beecham Corporation | Procede de traitement |
-
2000
- 2000-11-08 EP EP00977065A patent/EP1231921A4/fr not_active Withdrawn
- 2000-11-08 JP JP2001536156A patent/JP2003513926A/ja not_active Withdrawn
- 2000-11-08 WO PCT/US2000/030703 patent/WO2001034158A1/fr not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038687A1 (fr) * | 1998-12-23 | 2000-07-06 | Smithkline Beecham Corporation | Inhibiteurs de proteases |
WO2001095911A1 (fr) * | 2000-06-14 | 2001-12-20 | Smithkline Beecham Corporation | Inhibiteurs de proteases |
WO2002017924A1 (fr) * | 2000-09-01 | 2002-03-07 | Smithkline Beecham Corporation | Procede de traitement |
Non-Patent Citations (1)
Title |
---|
See also references of WO0134158A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1231921A1 (fr) | 2002-08-21 |
JP2003513926A (ja) | 2003-04-15 |
WO2001034158A1 (fr) | 2001-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL349192A1 (en) | Protease inhibitors | |
GB9912961D0 (en) | Metalloprotease inhibitors | |
IL150964A0 (en) | Protease inhibitors | |
EP1093367A4 (fr) | Inhibiteurs de proteases | |
IL145085A0 (en) | Dihetero-substituted metalloprotease inhibitors | |
EP1067894A4 (fr) | Inhibiteurs de protease | |
EP1235577A4 (fr) | Inhibiteurs de protease | |
EP1079821A4 (fr) | Inhibiteurs de la protease | |
IL153421A0 (en) | Protease inhibitors | |
EP1232155A4 (fr) | Inhibiteurs de protease | |
EP1231921A4 (fr) | Inhibiteurs de proteases | |
EP1229914A4 (fr) | Inhibiteurs de protease | |
EP1229912A4 (fr) | Inhibiteurs de protease | |
EP1229915A4 (fr) | Inhibiteurs de protease | |
EP1140897A4 (fr) | Inhibiteurs de proteases | |
EP1086083A4 (fr) | Inhibiteurs de proteases | |
IL151087A0 (en) | Protease inhibitors | |
HK1044758A1 (zh) | 蛋白酶抑制劑 | |
EP1229911A4 (fr) | Inhibiteurs de proteases | |
EP1351930A4 (fr) | Inhibiteurs de la protease | |
EP1161237A4 (fr) | Inhibiteurs de protease | |
EP1233771A4 (fr) | Inhibiteurs de protease | |
EP1231923A4 (fr) | Inhibiteurs de protease | |
EP1231922A4 (fr) | Inhibiteurs de protease | |
EP1232154A4 (fr) | Inhibiteurs de protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020603 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040507 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 19/08 B Ipc: 7A 61P 19/10 B Ipc: 7C 07D 409/14 B Ipc: 7A 61K 31/55 A |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060212 |